VPA23462/004/001

Ketamidor 100 mg/ml solution for injection

Variation	Summary	Date
Vet - B44 a)	VNRA - Vet - B44 a) Vet - B44 a) - Submission of a Ph.	
	Eur. CEP for:— active substance;— starting material,	10/11/25
	reagent or intermediate used in the manufacturing process	10/11/23
	of the active substance;— excipient - Updated cerificate	
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product	28/04/25
	information with version 9.0 (or the latest version of the	
	QRD templates that are in effect at the time that this	
	one-off variation is submitted) of the QRD templates i.e.	
	major update of the QRD templates in accordance with	
	Regulation (EU) 2019/6, for veterinary medicinal	
	products placed on the market in accordance with	
	Directive 2001/82/EC or Regulation (EC) No 726/2004 -	
	G.I.18 Safety, Efficacy, Pharmacovigilance changes -	
	One-off alignment of the product information with	
	version 9.0 (or the latest version of the QRD templates	
	that are in effect at the time that this one-off variation is	
	submitted) of the QRD templates i.e. major update of the	
	QRD templates in accordance with Regulation (EU)	
	2019/6, for veterinary medicinal products placed on the	
	market in accordance with Directive 2001/82/EC or	
	Regulation (EC) No 726/2004	
Vet - C1	VNRA - Vet - C1 - Change(s) in the name or address or	07/04/25
	contact details of a qualified person for	
	pharmacovigilance (QPPV) - C1 Changes to the safety,	
	efficacy and pharmacovigilance part of the dossier:	
	Change(s) in the name or address or contact details of a	
	qualified person for pharmacovigilance (QPPV)	
Vet - B44(Do not use)	VNRA - Vet - B44 - Submission of a new or updated Ph.	12/11/24
	Eur. CEP from an already approved manufacturer for a	
	non-sterile active substance, starting material, reagent or	
	intermediate, excipient - B44 Changes to the quality part	
	of the dossier: Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a	
	non-sterile: — active substance; — starting material,	
	reagent or intermediate used in the manufacturing process	
	of the active substance; — excipient	
	VNRA - Vet - B3 s) - s) Deletion of a supplier of	
	packaging components or devices - B3 s) Changes to the	
Vet - B3 s)	quality part of the dossier: Deletion of a supplier of	17/07/24
	packaging components or devices (when mentioned in the	11/0//2-T
	dossier)	
Vet - F.III.1 a) z.	VRA-S - Vet - F.III.1 a) z a) European Pharmacopoeial	
	Certificate of Suitability to the relevant Ph. Eur.	22/02/24
	Monograph. z) Other changes under this code level e.g.	

	1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	
	variations outlined in section 6 and 7 of	
	EMA/CMDv/7381/2021 - F.III.1 a) z. Quality Changes -	
	CEP/TSE/MONOGRAPHS -Submission of a new or	
	updated Ph. Eur. certificate of suitability or deletion of Ph.	
	Eur. certificate of suitability: -For an active substance -For	
	a starting material/reagent/intermediate used in the	
	manufacturing process of the active substance -For an	
	excipient European Pharmacopoeial Certificate of	
	Suitability to the relevant Ph. Eur. Monograph - Other	
	changes under this code level, e.g. variations outlined in	
	section 6 and 7 of EMA/CMDv/7381/2021	
	VRA-S - Vet - F.III.1 a) z a) European Pharmacopoeial	
	Certificate of Suitability to the relevant Ph. Eur.	
	Monograph. z) Other changes under this code level e.g.	
	variations outlined in section 6 and 7 of	22/02/24
	EMA/CMDv/7381/2021 - F.III.1 a) z. Quality Changes -	
	CEP/TSE/MONOGRAPHS -Submission of a new or	
	updated Ph. Eur. certificate of suitability or deletion of Ph.	
Vet - F.III.1 a) z.	Eur. certificate of suitability: -For an active substance -For	
	a starting material/reagent/intermediate used in the	
	manufacturing process of the active substance -For an	
	excipient European Pharmacopoeial Certificate of	
	Suitability to the relevant Ph. Eur. Monograph - Other	
	changes under this code level, e.g. variations outlined in	
	section 6 and 7 of EMA/CMDv/7381/2021	
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the	
	PSMF or changes to the summary of the PSMF not	
	already covered elsewhere in the Annex to Regulation	
	(EU) 2021/17 - C6 Changes to the safety, efficacy and	01/06/23
	pharmacovigilance part of the dossier: Introduction of a	
	summary of the PSMF or changes to the summary of the	
	PSMF not already covered elsewhere in the Annex to	
	Regulation (EU) 2021/17	
Vet - A1 e)	VNRA - Vet - A1 e) - e) Change in the name or address or	
	contact details of a manufacturer or importer of the	
	finished product (including batch release or quality	
	control testing sites) - A1 e) Administrative changes:	01/06/23
	Change in the name or address or contact details of a	01/00/23
	manufacturer or importer of the finished product	
	(including batch release or quality control testing sites)	
	I (merading batch release of quanty control testing sites)	